Global Molecular Targeted Diagnostics Market Assessment, By Product & Service [Reagents & Kits, Instruments and Services & Software], By Sample Type [Blood, Serum, and Plasma, Urine and Others], By Test Type [Lab Tests and PoC Tests], By Technology [Isothermal Nucleic Acid Amplification Technology, DNA Sequencing & Next-generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization and DNA Microarrays and Others], By Application [Infectious Disease Diagnostics, Oncology Testing, Genetic Testing and Others], End-user [Diagnostic Laboratories, Hospitals & Clinics and Others], By Region, Opportunities and Forecast, 2017-2031F
Global Molecular Targeted Diagnostics Market size was valued at USD 14.75 billion in 2023 which is expected to reach USD 25.47 billion in 2031 with a CAGR of 7.07% for the forecast period between 2024 and 2031.
Home>Industry Reports>Global Molecular Targeted Diagnostics Market Assessment, Opportunities and Forecast, 2017-2031F
Global molecular targeted diagnostics Market size was valued at USD 14.75 billion in 2023 which is expected to reach USD 25.47 billion in 2031 with a CAGR of 7.07% for the forecast period between 2024 and 2031. Various factors propel the growth and evolution of the global molecular targeted diagnostics market. Some of the drivers are growing need for companion diagnostics, advancements in technology, a surge in prevalence of chronic diseases, the emergence of personalized medicine, governmental initiatives, and increasing investment in research & development. One of the key drivers of global molecular targeted diagnostics market is the increasing demand for companion diagnostics, which plays a crucial role in tailoring treatments to individual patients by identifying specific biomarkers that assist in predicting treatment responses. Moreover, continuous advancements in technology have led to the development of advanced diagnostic tools that offer enhanced accuracy and precision, fostering the expansion of global molecular targeted diagnostics market. The increasing prevalence of chronic diseases including cancer, cardiovascular diseases, and infectious ailments, has amplified the necessity for reliable diagnostic techniques. Furthermore, the emergence of personalized medicine has revolutionized healthcare by emphasizing treatments tailored to an individual's genetic makeup and specific biomarkers.
Government initiatives supporting precision medicine and healthcare infrastructure expansion, coupled with increasing awareness and patient empowerment regarding the benefits of early diagnosis and targeted treatments, have significantly propelled the adoption of molecular targeted diagnostics. Additionally, significant investments in research and development by pharmaceutical and biotech companies aim to innovate and improve diagnostic tools, fostering growth in global molecular targeted diagnostics market by enhancing accuracy, efficacy, and accessibility.
Advent of Personalized Medicine
The emergence of personalized medicine is a pivotal driver propelling the global molecular targeted diagnostics market. This approach tailors’ treatments according to patients' unique genetic profiles, biomarkers, and characteristics. Precision diagnostic tools, like molecular targeted diagnostics, are important for identifying specific genetic alterations and biomarkers critical for determining treatment strategies. These diagnostics tools serve a crucial role by guiding targeted therapies, forecasting treatment outcomes, and enhancing patient responses. As the demand increases for personalized treatments that cater to individual patient needs, the importance of personalized medicine will also increase. Consequently, this surge in significance fuels the broader adoption and utilization of molecular targeted diagnostics across various healthcare settings worldwide. This symbiotic relationship between personalized medicine and molecular targeted diagnostics signifies a transformative shift toward more individualized and effective patient care strategies within the global healthcare landscape.
Increasing in Investments in Research & Development
Technological developments in diagnostic technologies are being driven by increased funding for research and development. These financial investments help develop more accurate, efficient, and widely available diagnostic tools. Additionally, they assist in validating and approving complicated diagnostic tests, broadening their usage across various healthcare domains. This increased funding substantially contributes to the market's expansion by improving diagnostic precision and effectiveness and, ultimately, fostering enhanced patient care on a larger scope. In August 2023, significant financial support was given to researchers at the City of Hope Medical Centre in California to develop a novel targeted chemotherapy. The new targeted chemotherapy showed promising results against all solid tumors in preclinical studies. Targeting proliferating cell nuclear antigen (PCNA), a protein that had been "undruggable," the novel drug candidate AOH1996 appears to eliminate all solid tumors related to PCNA.
Numerous Clinical Benefits of In Situ Hybridization
In situ hybridization (ISH) serves a critical function by allowing visualization and recognition of precise nucleic acid sequences within cells or tissues. This method assists in identifying gene expressions, changes, or disease-causing components, thereby aiding precise disease identification and tailored treatment approaches. As healthcare prioritizes targeted and personalized therapies more, the increased demand for precise molecular diagnostics, notably ISH, fosters the growth of global molecular targeted diagnostics market. This demand facilitates accurate identification and understanding of biomarkers, elevating diagnostic capacities across different diseases globally. In May 2023, Bio-Techne, revealed enhancements in advanced cell diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) range. This extension involves the introduction of an RNAscope multiomic workflow designed for the Standard BioTools Hyperion Imaging System.
Government Initiatives
Governments actively participate in initiatives to enhance molecular targeted diagnostics by creating specialized research hubs. These initiatives are intended to progress research, foster innovation, and encourage the adoption of state-of-the-art diagnostic technologies. By nurturing environments conducive to research and development, these undertakings drive the growth and development of the global molecular targeted diagnostics market. These coordinated government initiatives stimulate technological progress and endorse the validation and assimilation of innovative diagnostic instruments, ultimately augmenting healthcare capabilities and advancing the quality of patient care globally. For instance, in August 2023, Kalyan Singh Super Specialty Cancer Institute (KSSSCI), a distinguished establishment operated by the Government of Uttar Pradesh, collaborated with Karkinos Healthcare and the Indian Institute of Technology Kanpur. This impactful three-way alliance signifies the launch of the 'Centre for Advanced Molecular Diagnostics and Research for Cancer (CAMDRC)', slated to be established in Lucknow.
Growing Demand for Infectious Disease Diagnostics
The rising demand for infectious disease diagnostics acts as a fundamental force propelling the global molecular targeted diagnostics market. This increase in demand arises from the essential need for precise, swift, and specialized diagnostic instruments to detect viruses, bacteria, or parasites accurately. Molecular targeted diagnostics is responsible for promptly identifying and characterizing these infectious agents, allowing for timely treatment choices and strategies to control infections. With persistent challenges posed by infectious diseases in the global healthcare scenario, the amplified necessity for accurate diagnostic tools drives the worldwide expansion and uptake of molecular targeted diagnostics. In April 2023, Thermo Fisher Scientific introduced the inaugural set of 37 CE-IVD-marked real-time PCR assay kits. Primarily designed for diagnosing infectious diseases, these kits are part of the company's plan to unveil a total of 37 such kits within the year. This launch signifies the introduction of Thermo Fisher Scientific's own company-branded test kits, enabling users of its QuantStudio Dx series of instruments to access a diverse range of testing options for the first time.
Outlook of Global Molecular Targeted Diagnostics Market
The future expansion prospects of the global molecular targeted diagnostics market are substantial. Technological advancements, especially in genomics, proteomics, and molecular biology, pave the path for more refined and thorough diagnostic tools. The rising prevalence of chronic illnesses, infectious diseases, and cancer cases on a global scale fuels the need for early detection and personalized therapies, fostering the adoption of molecular targeted diagnostics. Furthermore, the paradigm shifts toward personalized medicine, focusing on customized treatments rooted in individual genetic profiles, intensifies the demand for precise diagnostic methods. Ongoing investments in research and development by pharmaceutical and biotech firms aim to innovate and refine diagnostic precision. Government initiatives backing precision medicine and healthcare infrastructure also play pivotal roles in market growth. As healthcare professionals and patients become increasingly aware of the advantages of early diagnosis, the global molecular targeted diagnostics market is positioned for substantial expansion, leading to improved patient care and treatment outcomes worldwide.
Report Scope
“Molecular Targeted Diagnostics Market Assessment, Opportunities, and Forecast, 2017-2031F”, is a comprehensive report by Market and Data, providing in-depth analysis and assessment of the current scenario of the global molecular targeted diagnostics market, industry dynamics and opportunities, and forecasts (2024-2031). Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
In this report, global molecular targeted diagnostics market has been segmented into the following categories:
· By Product and Service
o Reagents & Kits
o Instruments
o Services & Software
· By Sample Type
o Blood, Serum, and Plasma
o Urine
o Others
· By Test Type
o Lab Tests
o PoC Tests
· By Technology
o Isothermal Nucleic Acid Amplification Technology
o DNA Sequencing & Next-generation Sequencing
o Polymerase Chain Reaction
o In Situ Hybridization
o DNA Microarrays
o Next Generation Sequencing
· By Application
o Infectious Disease Diagnostics
§ Hepatitis
§ HPV
§ HIV
§ HAI
§ CT/NG
§ Tuberculosis
§ Influenza
§ Others
o Oncology Testing
§ Lung Cancer
§ Prostate Cancer
§ Breast Cancer
§ Colorectal Cancer
§ Others
o Genetic Testing
o Blood Testing
o Others
· End-user
o Hospitals & Clinics
o Diagnostic Laboratories
o Others
· By Region
o North America
o South America
o Europe
o Asia-Pacific
o Middle East and Africa
Key Players Landscape and Outlook
Many companies in the global molecular targeted diagnostics market are actively participating in strategic partnerships. These alliances seek to merge knowledge, technologies, and resources to create advanced diagnostic tools. Collaborations facilitate the integration of various expertise and research capabilities, expediting the development of precise and efficient diagnostic solutions. Through leveraging collective strengths, companies navigate complexities, expanding market presence. These collaborations foster synergy, advancing the progress and acceptance of molecular targeted diagnostics. Consequently, they offer improved diagnostic accuracy and effectiveness, ultimately benefiting healthcare systems and global patients. In February 2023, Thermo Fisher Scientific disclosed that its Applied Biosystems TaqPath PCR kits used in diagnosing infectious diseases like multi-drug-resistant tuberculosis (MTB MDR), M. tuberculosis complex (MTB), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and for genetic analysis (HLA B27) have obtained licensing approval from the Central Drugs Standard Control Organisation (CDSCO). Thermo Fisher Scientific will collaborate with Mylab Discovery Solutions to produce these kits in India.
Key Players Operating in Global Molecular Targeted Diagnostics Market are:
· F. Hoffmann-La Roche Ltd.
· Novartis AG
· Abbott Laboratories
· Becton, Dickinson, and Company
· Siemens Healthineers
· Agilent Technologies, Inc.
· Hologic, Inc.
· bioMerieux SA
· QIAGEN Biotechnology Malaysia Sdn Bhd.
· Danaher Corporation
· Illumina, Inc.
· Thermo Fisher Scientific Inc.
Markets and Data’s reports answer the following questions:
• What is the current and future market size of the product/service in question globally or specific to different countries?
• How are the markets divided into different product/service segments and the market size and growth of each segment?
• What is the market potential of different product segments and their investment case?
• How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
• What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global molecular targeted diagnostics market, you may approach our team at info@marketsandata.com.
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Outlook of Global Molecular Targeted Diagnostics Market
4. Executive Summary
5. Global Molecular Targeted Diagnostics Market Outlook, 2017-2031F
5.1. Market Size & Forecast
5.1.1.Value
5.1.2.Volume
5.2.2.Instruments
5.2.3.Services & Software
5.3. By Sample Type
5.3.1.Blood, Serum, and Plasma
5.3.2.Urine
5.3.3.Others
5.4. By Test Type
5.4.1.Lab Tests
5.4.2.PoC Tests
5.5. By Technology
5.5.1.Isothermal Nucleic Acid Amplification Technology
5.5.2.DNA Sequencing & Next-generation Sequencing
5.5.3.Polymerase Chain Reaction
5.5.4.In Situ Hybridization
5.5.5.DNA Microarrays
5.5.6.Next Generation Sequencing
5.5.7.Others
5.6. By Application
5.6.1.Infectious Disease Diagnostics
5.6.1.1. Hepatitis
5.6.1.2. HPV
5.6.1.3. HIV
5.6.1.4. HAI
5.6.1.5. CT/NG
5.6.1.6. Tuberculosis
5.6.1.7. Influenza
5.6.1.8. Others
5.6.2.Oncology Testing
5.6.2.1. Lung Cancer
5.6.2.2. Prostate Cancer
5.6.2.3. Breast Cancer
5.6.2.4. Colorectal Cancer
5.6.2.5. Others
5.6.3.Genetic Testing
5.6.4.Blood Testing
5.6.5.Others
5.7. By End-user
5.7.1.Hospitals & Clinics
5.7.2.Diagnostic Laboratories
5.7.3.Others
5.8. By Region
5.8.1.North America
5.8.2.Europe
5.8.3.South America
5.8.4.Asia-Pacific
5.8.5.Middle East and Africa
5.9. By Company Market Share (%), 2022
6. Global Molecular Targeted Diagnostics Market Outlook, By Region, 2017-2031F
6.1. North America*
6.1.1. By Product
6.1.1.1. Reagents & Kits
6.1.1.2. Instruments
6.1.1.3. Services & Software
6.1.2. By Sample Type
6.1.2.1. Blood, Serum, and Plasma
6.1.2.2. Urine
6.1.2.3. Others
6.1.3. By Test Type
6.1.3.1. Lab Tests
6.1.3.2. PoC Tests
6.1.4. By Technology
6.1.4.1. Isothermal Nucleic Acid Amplification Technology
6.1.4.2. DNA Sequencing & Next-generation Sequencing
6.1.4.3. Polymerase Chain Reaction
6.1.4.4. In Situ Hybridization
6.1.4.5. DNA Microarrays
6.1.4.6. Next Generation Sequencing
6.1.4.7. Others
6.1.5. By Application
6.1.5.1. Infectious Disease Diagnostics
6.1.5.1.1. Hepatitis
6.1.5.1.2. HPV
6.1.5.1.3. HIV
6.1.5.1.4. HAI
6.1.5.1.5. CT/NG
6.1.5.1.6. Tuberculosis
6.1.5.1.7. Influenza
6.1.5.1.8. Others
6.1.5.2. Oncology Testing
6.1.5.2.1. Lung Cancer
6.1.5.2.2. Prostate Cancer
6.1.5.2.3. Breast Cancer
6.1.5.2.4. Colorectal Cancer
6.1.5.2.5. Others
6.1.5.3. Genetic Testing
6.1.5.4. Blood Testing
6.1.5.5. Others
6.1.6. By End-user
6.1.6.1. Hospitals & Clinics
6.1.6.2. Diagnostic Laboratories
6.1.6.3. Others
6.1.7. United States*
6.1.7.1. By Product
6.1.7.1.1. Reagents & Kits
6.1.7.1.2. Instruments
6.1.7.1.3. Services & Software
6.1.7.2. By Sample Type
6.1.7.2.1. Blood, Serum, and Plasma
6.1.7.2.2. Urine
6.1.7.2.3. Others
6.1.7.3. By Test Type
6.1.7.3.1. Lab Tests
6.1.7.3.2. PoC Tests
6.1.7.4. By Technology
6.1.7.4.1. Isothermal Nucleic Acid Amplification Technology
6.1.7.4.2. DNA Sequencing & Next-generation Sequencing
6.1.7.4.3. Polymerase Chain Reaction
6.1.7.4.4. In Situ Hybridization
6.1.7.4.5. DNA Microarrays
6.1.7.4.6. Next Generation Sequencing
6.1.7.4.7. Others
6.1.7.5. By Application
6.1.7.5.1. Infectious Disease Diagnostics
6.1.7.5.1.1. Hepatitis
6.1.7.5.1.2. HPV
6.1.7.5.1.3. HIV
6.1.7.5.1.4. HAI
6.1.7.5.1.5. CT/NG
6.1.7.5.1.6. Tuberculosis
6.1.7.5.1.7. Influenza
6.1.7.5.1.8. Others
6.1.7.5.2. Oncology Testing
6.1.7.5.2.1. Lung Cancer
6.1.7.5.2.2. Prostate Cancer
6.1.7.5.2.3. Breast Cancer
6.1.7.5.2.4. Colorectal Cancer
6.1.7.5.2.5. Others
6.1.7.5.3. Genetic Testing
6.1.7.5.4. Others
6.1.7.6. By End-user
6.1.7.6.1.1. Hospital & Clinics
6.1.7.6.1.2. Diagnostic Laboratories
6.1.7.6.1.3. Others
6.1.7.7. Canada
6.1.7.8. Mexico
*All segments will be provided for all regions and countries covered
6.2. Europe
6.2.1 Germany
6.2.2 France
6.2.3 Italy
6.2.4 United Kingdom
6.2.5 Russia
6.2.6 Netherlands
6.2.7 Spain
6.2.8 Turkey
6.2.9 Poland
6.3. South America
6.3.1. Brazil
6.3.2. Argentina
6.4. Asia-Pacific
6.4.1. India
6.4.2. China
6.4.3. Japan
6.4.4. Australia
6.4.5. Vietnam
6.4.6. South Korea
6.4.7. Indonesia
6.4.8. Philippines
6.5. Middle East & Africa
6.5.1. Saudi Arabia
6.5.2. UAE
6.5.3. South Africa
7. Market Mapping, 2023
7.1. By Product
7.2. By Sample Type
7.3. By Test Type
7.4. By Technology
7.5. By Application
7.6. By End-user
7.7. By Region
8. Macro Environment and Industry Structure
8.1. Supply Demand Analysis
8.2. Import Export Analysis
8.3. Value Chain Analysis
8.4. PESTEL Analysis
8.4.1. Political Factors
8.4.2. Economic System
8.4.3. Social Implications
8.4.4. Technological Advancements
8.4.5. Environmental Impacts
8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
8.5. Porter’s Five Forces Analysis
8.5.1. Supplier Power
8.5.2. Buyer Power
8.5.3. Substitution Threat
8.5.4. Threat from New Entrant
8.5.5. Competitive Rivalry
9. Market Dynamics
9.1. Growth Drivers
9.2. Growth Inhibitors (Challenges and Restraints)
10. Regulatory Framework and Innovation
10.1 Clinical Trials
10.2 Patent Landscape
10.3 Regulatory Approvals
10.4 Innovations/Emerging Technologies
11. Key Players Landscape
11.1. Competition Matrix of Top Five Market Leaders
11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4. SWOT Analysis (For Five Market Players)
11.5. Patent Analysis (If Applicable)
12. Pricing Analysis
13. Case Studies
14. Key Players Outlook
14.1. F. Hoffmann-La Roche Ltd.
14.1.1. Company Details
14.1.2. Key Management Personnel
14.1.3. Products & Services
14.1.4. Financials (As reported)
14.1.5. Key Market Focus & Geographical Presence
14.1.6. Recent Developments
14.2. Novartis AG
14.3. Abbott Laboratories
14.4. Becton, Dickinson, and Company
14.5. Siemens Healthineers
14.6. Agilent Technologies, Inc.
14.7. Hologic, Inc.
14.8. bioMerieux SA
14.9. QIAGEN Biotechnology Malaysia Sdn Bhd.
14.10. Danaher Corporation
14.11. Illumina, Inc.
14.12. Thermo Fisher Scientific Inc.
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
15. Strategic Recommendations
14. About Us & Disclaimer
List of Figures
Figure 1. Global Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 4. Global Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 5. Global Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 6. Global Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 7. Global Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 8. Global Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 9. Global Molecular Targeted Diagnostics Market Share (%), By Region, 2017-2031F
Figure 10. North America Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 11. North America Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 12. North America Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 13. North America Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 14. North America Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 15. North America Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 16. North America Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 17. North America Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 18. North America Molecular Targeted Diagnostics Market Share (%), By Country, 2017-2031F
Figure 19. United States Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 20. United States Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 21. United States Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 22. United States Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 23. United States Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 24. United States Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 25. United States Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 26. United States Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 27. Canada Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 28. Canada Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 29. Canada Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 30. Canada Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 31. Canada Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 32. Canada Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 33. Canada Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 34. Canada Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 35. Mexico Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 36. Mexico Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 37. Mexico Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 38. Mexico Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 39. Mexico Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 40. Mexico Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 41. Mexico Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 42. Mexico Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 43. Europe Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 44. Europe Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 45. Europe Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 46. Europe Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 47. Europe Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 48. Europe Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 49. Europe Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 50. Europe Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 51. Europe Molecular Targeted Diagnostics Market Share (%), By Country, 2017-2031F
Figure 52. Germany Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 53. Germany Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 54. Germany Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 55. Germany Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 56. Germany Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 57. Germany Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 58. Germany Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 59. Germany Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 60. France Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 61. France Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 62. France Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 63. France Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 64. France Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 65. France Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 66. France Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 67. France Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 68. Italy Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 69. Italy Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 70. Italy Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 71. Italy Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 72. Italy Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 73. Italy Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 74. Italy Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 75. Italy Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 76. United Kingdom Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 77. United Kingdom Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 78. United Kingdom Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 79. United Kingdom Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 80. United Kingdom Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 81. United Kingdom Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 82. United Kingdom Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 83. United Kingdom Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 84. Russia Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 85. Russia Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 86. Russia Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 87. Russia Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 88. Russia Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 89. Russia Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 90. Russia Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 91.
Figure 92. Russia Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 93. Netherlands Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 94. Netherlands Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 95. Netherlands Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 96. Netherlands Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 97. Netherlands Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 98. Netherlands Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 99. Netherlands Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 100. Netherlands Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 101. Spain Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 102. Spain Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 103. Spain Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 104. Spain Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 105. Spain Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 106. Spain Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 107. Spain Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 108. Spain Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 109. Turkey Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 110. Turkey Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 111. Turkey Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 112. Turkey Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 113. Turkey Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 114. Turkey Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 115. Turkey Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 116. Turkey Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 117. Poland Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 118. Poland Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 119. Poland Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 120. Poland Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 121. Poland Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 122. Poland Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 123. Poland Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 124. Poland Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 125. South America Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 126. South America Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 127. South America Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 128. South America Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 129. South America Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 130. South America Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 131. South America Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 132. South America Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 133. South America Molecular Targeted Diagnostics Market Share (%), By Country, 2017-2031F
Figure 134. Brazil Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 135. Brazil Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 136. Brazil Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 137. Brazil Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 138. Brazil Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 139. Brazil Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 140. Brazil Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 141. Brazil Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 142. Argentina Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 143. Argentina Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 144. Argentina Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 145. Argentina Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 146. Argentina Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 147. Argentina Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 148. Argentina Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 149. Argentina Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 150. Asia-Pacific Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 151. Asia-Pacific Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 152. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 153. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 154. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 155. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 156. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 157. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 158. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Country, 2017-2031F
Figure 159. India Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 160. India Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 161. India Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 162. India Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 163. India Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 164. India Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 165. India Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 166. India Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 167. China Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 168. China Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 169. China Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 170. China Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 171. China Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 172. China Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 173. China Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 174. China Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 175. Japan Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 176. Japan Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 177. Japan Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 178. Japan Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 179. Japan Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 180. Japan Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 181. Japan Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 182. Japan Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 183. Australia Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 184. Australia Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 185. Australia Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 186. Australia Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 187. Australia Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 188. Australia Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 189. Australia Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 190. Australia Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 191. Vietnam Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 192. Vietnam Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 193. Vietnam Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 194. Vietnam Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 195. Vietnam Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 196. Vietnam Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 197. Vietnam Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 198. Vietnam Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 199. South Korea Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 200. South Korea Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 201. South Korea Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 202. South Korea Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 203. South Korea Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 204. South Korea Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 205. South Korea Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 206. South Korea Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 207. Indonesia Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 208. Indonesia Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 209. Indonesia Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 210. Indonesia Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 211. Indonesia Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 212. Indonesia Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 213. Indonesia Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 214. Indonesia Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 215. Philippines Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 216. Philippines Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 217. Philippines Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 218. Philippines Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 219. Philippines Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 220. Philippines Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 221. Philippines Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 222. Philippines Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 223. Middle East & Africa Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 224. Middle East & Africa Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 225. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 226. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 227. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 228. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 229. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 230. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 231. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Country, 2017-2031F
Figure 232. Saudi Arabia Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 233. Saudi Arabia Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 234. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 235. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 236. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 237. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 238. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 239. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 240. UAE Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 241. UAE Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 242. UAE Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 243. UAE Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 244. UAE Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 245. UAE Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 246. UAE Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 247. UAE Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 248. South Africa Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 249. South Africa Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 250. South Africa Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
Figure 251. South Africa Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 252. South Africa Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
Figure 253. South Africa Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
Figure 254. South Africa Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
Figure 255. South Africa Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 256. By Product and Service Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 257. By Sample Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 258. By Test Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 259. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 260. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 261. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 262. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What regions are covered in the final report for global molecular targeted diagnostics market?
Who are the key players operating in the global molecular targeted diagnostics market?
What are the major factors influencing the growth of global molecular targeted diagnostics market?
What is the market size and growth rate of global molecular targeted diagnostics market?
See Related Reports
Global Coffee Market Assessment, Opportunities and Forecast, 2017-2031F
Global coffee market is expected to experience growth due to consumers’ increasing preference for organic and premium coffee that offers freshness, superior quality of beans and roasts, and unique flavor profile. Additionally, the product innovation,....Read More
Published on
July 2024
4,500
Global Home Theater System Market Assessment, Opportunities and Forecast, 2017-2031F
Global home theater system market is expected to experience growth due to technological advancements, increasing disposable incomes, rising demand for high-definition content, integration with smart home systems, and the surge in streaming services p....Read More
Published on
July 2024
4,500
Global Baby Food Market Assessment, Opportunities and Forecast, 2017-2031F
Global baby food market is expected to experience growth due to factors such as consumers’ increasing awareness of the nutrients which are essential for babies development and introduction of wide variety of baby foods in the market from milk powders....Read More
Published on
July 2024
4,500
Global Isoflavones Market Assessment, Opportunities and Forecast, 2017-2031F
Global isoflavones market is expected to experience growth due to increasing consumer health awareness, rising demand for functional foods and nutraceuticals, advancements in extraction technologies, and expanding applications in cosmetics, pharmaceu....Read More
Published on
July 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
